EUCR
Eucrates Biomedical Acquisition
EUCR | NASDAQ
$10.04
$0.00 (0.00%)
At close: Apr 26, 2023, 03:14 PM ET
Eucrates Biomedical Acquisition Company Profile
Company profile explainedCompany Profile
Eucrates Biomedical Acquisition Corp. currently lacks substantial business operations. Its primary objective is to execute a corporate transaction such as a merger, stock swap, asset purchase, equity acquisition, restructuring, or another comparable strategic alliance involving one or more enterprises. Specifically, it aims to find and acquire a company operating within the life sciences or broader healthcare sectors across North America and Europe. Established in 2020, this entity has its headquarters situated in New York, New York.
Key Executives
| Name | Position |
|---|---|
| Parag Phoolchand Saxena | Chief Executive Officer & Director |
| Evangelos Vergetis | Pres, Chief Operating Officer & Director |
| Gonzalo Cordova | Chief Financial Officer |
| Shrikant Sathe | Senior Vice President |
Eucrates Biomedical Acquisition
EUCR
| Country | United States |
| IPO Date | Dec 28, 2020 |
| Industry | Shell Companies |
| Sector | Financial Services |
| Employees | n/a |
| CEO | Parag Phoolchand Saxena MBA, MS |
Stock Details
| Ticker Symbol | EUCR |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001822929 |
| CUSIP Number | G3141W106 |
| ISIN Number | VGG3141W1068 |
| SIC Code | 6770 |
Add to Watchlist
Select watchlists to add or remove EUCR